AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
CD
Chai DiscoveryChai Discovery builds generative AI foundation models that predict and design protein and antibody structures to accelerate pre-clinical drug discovery.
2 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
$600M
Attovia TherapeuticsChai Discovery
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
$3.8B
Attovia TherapeuticsChai Discovery
Biotech
Sector
Biotech
2023
Founded
2024
San Carlos, CA
HQ
San Francisco, CA
Public (ATTO)
Status
Private
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Chai Discovery investors
Index VenturesSequoia CapitalDimensionKleiner Perkins
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Chai Discovery.